Marshall Wace
GALT icon

Marshall Wace’s Galectin Therapeutics GALT Stock Holding History

Marshall Wace’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Sell
831,010
-388,902
-32% -$1.01M ﹤0.01% 1500
2026
Q1 		$3.4M Buy
1,219,912
+617,778
+103% +$1.88M ﹤0.01% 1505
2025
Q4 		$2.5M Buy
602,134
+47,873
+9% +$252K ﹤0.01% 1467
2025
Q3 		$2.35M Buy
554,261
+523,861
+1,723% +$1.97M ﹤0.01% 1534
2025
Q2 		$64.1K Buy
+30,400
New +$45.5K ﹤0.01% 2577
2024
Q4 		– Sell
-52,259
Closed -$144K – 2724
2024
Q3 		$144K Buy
52,259
+33,434
+178% +$82.1K ﹤0.01% 2334
2024
Q2 		$42.5K Buy
+18,825
New +$57.2K ﹤0.01% 2454
2021
Q3 		– Sell
-47,509
Closed -$152K – 3161
2021
Q2 		$152K Buy
+47,509
New +$169K ﹤0.01% 2494

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace's GALT Position: Q2 2026 in Review

Marshall Wace reduced its Galectin Therapeutics (GALT) stake by 32% in Q2 2026, selling an estimated $1.01M and leaving 831,010 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Marshall Wace first reported a position in GALT in Q2 2021 and has held it in 8 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Marshall Wace held 831,010 shares of Galectin Therapeutics worth $3.86M as of Q2 2026.
  • Marshall Wace sold 388,902 Galectin Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Galectin Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1500 holding.
  • Marshall Wace first reported a position in Galectin Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.